Mechanism of Action
EGFR Activation and Downstream Signaling
EGF binds to the extracellular domain of EGFR with picomolar-range affinity, inducing receptor homodimerization (EGFR/EGFR) or heterodimerization with ErbB2, ErbB3, or ErbB4. Dimerization activates the intracellular tyrosine kinase domain, leading to autophosphorylation at multiple tyrosine residues that serve as docking sites for signaling adaptors. The Ras/Raf/MEK/ERK (MAPK) cascade drives cell cycle entry and proliferation. The PI3K/Akt/mTOR pathway promotes cell survival and protein synthesis. STAT3/5 activation contributes to transcriptional programs for wound healing gene expression. EGFR signaling is one of the most studied and clinically relevant pathways in oncology, it is the target of multiple FDA-approved cancer drugs (cetuximab, erlotinib, gefitinib).
Wound Healing Mechanisms
In wound healing, EGF has three coordinated roles. First, it stimulates keratinocyte and fibroblast migration into the wound bed through actin cytoskeletal remodeling and focal adhesion dynamics. Second, it drives proliferation to replenish cells consumed by the wound repair process. Third, it stimulates collagen synthesis in dermal fibroblasts, promoting the extracellular matrix reconstitution phase of healing. EGF also promotes angiogenesis via VEGF upregulation, ensuring blood supply to regenerating tissue. The combination of migration, proliferation, and matrix deposition makes EGF one of the most comprehensive healing growth factors.
Skin Rejuvenation Biology
In aged skin, EGFR expression and signaling competence decline, contributing to reduced keratinocyte turnover, thinner epidermis, impaired barrier function, and slower wound healing. Exogenous EGF restores EGFR-driven proliferation and differentiation programs in aged keratinocytes. Collagen type I and III production increases in EGF-treated dermal fibroblasts. This biological rationale supports EGF's use in anti-aging and skin rejuvenation contexts, where improvements in skin thickness, hydration, wrinkle depth, and wound healing speed have been documented in small controlled trials.
Research Summary
Chronic Wounds and Diabetic Ulcers
Phase II/III ClinicalThe strongest clinical evidence for EGF is in chronic wound healing. A meta-analysis of 7 RCTs (n=459) of topical or intradermal rh-EGF for diabetic foot ulcers showed significantly higher complete healing rates (RR 1.63) and faster time to closure versus control. Intradermal injection around wound edges is more effective than surface application due to better receptor access. Cuban Epidermal Growth Factor (Heberprot-P), intralesional EGF for diabetic foot - is approved in Cuba, Colombia, and several other countries, with Phase III data showing 71% complete healing versus 33% in controls.
Corneal and Ocular Healing
Phase II/III ClinicalEGFR is highly expressed in corneal epithelium. Topical EGF eye drops (0.5-100 mcg/mL) accelerate corneal epithelial healing after refractive surgery (LASIK, PRK) and in neurotrophic keratopathy. Phase II trials show significantly faster re-epithelialization compared to artificial tears alone. EGF is incorporated into some commercial post-LASIK eye drop formulations in Asia.
Skin Rejuvenation
Moderate EvidenceSmall controlled trials of topical EGF serums (10-100 ng/mL applied daily for 4-12 weeks) show statistically significant improvements in skin hydration, wrinkle depth (Visia imaging), epidermal thickness (ultrasound), and collagen density (reflectance confocal microscopy) versus vehicle control. The effect size is modest but consistent. EGF is stable in well-formulated topical products and penetrates the outer epidermis where EGFR-expressing keratinocytes reside.
Calculate your EGF dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Chronic wound / diabetic ulcer | 75-150 mcg intradermal | Every 3 days, 8-12 injections | Intradermal perilesional |
| Systemic healing acceleration | 50-100 mcg SC | Daily or EOD, 2-4 weeks | Subcutaneous |
| Post-surgical skin recovery | 50 mcg SC | Daily for 2 weeks | Subcutaneous |
| Topical skin rejuvenation | 50-100 ng/mL topical | Daily application | Topical serum |
EGF is highly susceptible to degradation by UV light and proteases. Store reconstituted solution at 4 C in amber vials; use within 48-72 h. For topical use, EGF requires encapsulation (liposomal or polysaccharide) to maintain stability in formulated products. Do not heat solutions above 25 C.
Interactions
Safety Profile
rh-EGF has an excellent safety record in wound healing trials with no serious systemic adverse events at typical research doses. Common local effects: mild burning or stinging at injection site, transient erythema. The critical safety consideration is oncological: EGFR signaling is mitogenic, and EGFR is overexpressed and mutated in numerous cancers. EGF is contraindicated in active malignancy or known EGFR-driven tumors. In healthy wound healing contexts or for cosmetic application, the clinical evidence shows no cancer risk from short-term topical or SC EGF. Prolonged systemic EGF exposure at pharmacologic doses has not been tested in long-term human trials. Not WADA prohibited. Not FDA approved as standalone injectable drug; topical wound care uses vary by country. Not scheduled.
References
- [1]Cohen S. "Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal." J Biol Chem. 1962;237:1555-1562.
- [2]Fernandez-Montequin JI et al. "Intralesional injections of Citoprot-P (recombinant human EGF) in advanced diabetic foot ulcers with risk of amputation." Int Wound J. 2009;6(6):432-443.
- [3]Huang EJ, Reichardt LF. "Neurotrophins: roles in neuronal development and function." Annu Rev Neurosci. 2001;24:677-736. (Growth factor receptor signaling reference)